- Home
- About
- Warning Signs & Symptoms
- Ovarian Cancer Overview
- Prevention, Early Detection/Screening & Causes
- Genetics
- Types of Ovarian Cancer
- Diagnosis & Staging
- Treatment Overview
- Surgery
- Chemotherapy
- Radiology & Radiation Therapy
- Hormonal (Anti-Estrogen) Therapy
- Biological (Immunotherapy & Vaccine) Therapy
- Gene Therapy
- Alternative & Complementary Therapy
- Clinical Development
- Clinical Trials
- Coping
- Survivorship
- Ovarian Cancer Resources
- Contact
Libby's H*O*P*E*
*Helping*Ovarian Cancer Survivors*Persevere Through*Education
-
"Once you choose hope, anything is possible." -- Christopher Reeve
Ovarian Cancer News – Shared Google Reader- What it feels like to survive ovarian cancer - Times Online November 28, 2009What it feels like to survive ovarian cancerTimes OnlineIt was the only sign she had a life-threatening disease I was just 40 when I was diagnosed with ovarian cancer. That's pretty unusual — only 15% of cases ...
- Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin -- An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity November 28, 2009Chemotherapy 2009;55:391-398 (DOI:10.1159/000262452) (Source: Chemotherapy)
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors. November 23, 2009CONCLUSIONS: Robust ABT-888+TMZ efficacy is observed across a spectrum of tumor types, including orthotopic and metastatic implantation. As many TMZ nonresponsive tumors proved sensitive to ABT-888+TMZ, this novel combination may broaden the clinical use of TMZ beyond melanoma and glioma. Although TMZ resistance may be influenced by MGMT, neither MGMT nor ot […]
- Sagopilone, a microtubule stabilizer for the potential treatment of cancer. November 28, 2009Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs. 2009 Dec;10(12):1359-1371 Authors: Galmarini CM Sagopilone (ZK-EPO), under development by Bayer Schering Pharma AG, is a novel, fully synthetic epothilone B analog that is representative of a new class of microtubule-stabilizing agents that have a similar me […]
- Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. November 28, 2009Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol. 2009 Nov 24; Authors: Landriscina M, Amoroso MR, Piscazzi A, Esposito F BACKGROUND: Protein homeostasis is a highly complex network of molecular interactions governing the health and life span of the o […]
- Moms with Cancer November 28, 2009Moms with Cancer is a 501c3 non-profit organization whose primary goal is addressing the special needs of Moms dealing with cancer treatments and recovery.A cancer diagnosis can financially and emotionally devastate some families. The extra deductibles, co-pays, tests, and medications are very costly. Moms with Cancer believes that any mom battling this dis […]
- Activation of hedgehog signaling is not a frequent event in ovarian cancers - 7thSpace Interactive (press release) November 27, 2009Activation of hedgehog signaling is not a frequent event in ovarian cancers7thSpace Interactive (press release)Activation of hedgehog signaling has been reported in about 30% of human cancer including ovarian cancer. Inhibition of hedgehog signaling has been pursued ...
- Screening: Diagnostic markers for ovarian cancer November 27, 2009Nature Reviews Clinical Oncology 6, 678 (2009). doi:10.1038/nrclinonc.2009.175 Author: Vessela Vassileva (Source: Nature Clinical Practice Oncology)
- PARP inhibitors and the treatment of breast cancers: beyond BRCA1/2? November 25, 2009PARP inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent […]
- Use of fertility drugs and risk of uterine cancer November 25, 2009Source: Am J Epidemiol Area: News In contrast to the fairly large number of studies that have investigated the association between fertility drugs and ovarian cancer and breast cancer, only a few epidemiological studies have assessed the link with uterine cancer and findings from these studies have been conflicting. Therefore researchers established a cohort […]
- Patient Money: Seeking the Best Medical Care Prices November 28, 2009With out-of-pocket expenses rising, it pays to look for better deals. Web sites and insiders’ tactics can help.
- [Place of autologous and allogeneic hematopoietic stem cell transplantation in ovarian cancer.] November 28, 2009[Place of autologous and allogeneic hematopoietic stem cell transplantation in ovarian cancer.] Bull Cancer. 2009 Nov 26; Authors: Nayl B, Cabrespine-Faugeras A, Maliki Y, Bay JO For several years, research for treatment of advanced ovarian cancer in first line or in relapse was made on the basis of two concepts. The first one is to improve the response rate […]
- Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. November 28, 2009Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-1946 Authors: Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, Scambia G Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity d […]
- Oral etoposide for refractory or recurrent epithelial ovarian cancer. November 28, 2009Oral etoposide for refractory or recurrent epithelial ovarian cancer. J Med Assoc Thai. 2009 Nov;92(11):1397-405 Authors: Thavaramara T, Tangjitgamol S, Manusirivithaya S, Leelahakorn S OBJECTIVE: To study the response rate (RR), toxicity, progression-free survival (PFS), and overall survival (OS) of the patients with recurrent or refractory epithelial ovari […]
- West Carleton author takes a humorous, insightful look at chemotherapy in book - EMC West Carleton November 27, 2009West Carleton author takes a humorous, insightful look at chemotherapy in bookEMC West CarletonWhat Colour is My Ribbon is a living journal that takes a courageous woman and her network of friends through her journey fighting ovarian cancer. ...and more »
- New Breast Cancer Recommendation May Cost Lives While Saving Money November 20, 2009Longtime OB/GYN warns against the new breast cancer recommendations released by the U.S. Preventative Services Task Force. These guidelines may be cost-effective, but they come at the price of human lives. When is it wrong to be safe than sorry?/I/P PThe new U.S. Preventative Services T...
- New federal law will prohibit discrimination in hiring and health insurance ... - Fort Worth Star Telegram November 27, 2009New federal law will prohibit discrimination in hiring and health insurance ...Fort Worth Star TelegramFor Cunningham, 48, of Fort Worth, that means her mother's death from ovarian cancer and her sister's fight with ovarian, breast and now uterine cancer ...
- Research Conducted At Cleveland Clinic Has Updated Our Knowledge About Gynecologic Cancer November 26, 2009According to a study from the United States, Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions.
- Herbal supplements may raise blood lead levels November 26, 2009NEW YORK (Reuters Health) - Some herbal supplements may boost the levels of lead in the blood of women, new research shows.
- Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. November 28, 2009Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs. 2009 Nov 24; Authors: Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P Malignant ascites resistant to conventional drugs frequently […]
- What it feels like to survive ovarian cancer - Times Online November 28, 2009
-
- Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, (ii) receive Libby's H*O*P*E* (tm) updates via email; or (iii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.
- New Ovarian Cancer Clinical Trials (Past 14 Days)
- Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer November 19, 2009
- An Open Label Extension Study of the Efficacy of MORAb-003 November 18, 2009
- A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer November 16, 2009
- Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant November 20, 2009
- Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome November 24, 2009
-
Recent Comments
Raj on Novel Targeted Gene Therapies … Paul Cacciatore on White Blood Cells Obtained Fro… joe t on White Blood Cells Obtained Fro… Paul Cacciatore on Massachusetts General Hospital… Paul Cacciatore on Gloria Johns Was Told “O… Rose Lopez on Massachusetts General Hospital… allison on Gloria Johns Was Told “O… Paul Cacciatore on Working Smarter, Not Harder: U… Kathie C on Working Smarter, Not Harder: U… Gregory D. Pawelski on Avastin Used in Combination wi… Gregory D. Pawelski on Modified Chemo Regime Increase… ovary2009 on Young Early-Stage Ovarian Canc… Pat on Barack Obama Proclaims Septemb… Paul Cacciatore on Novel Targeted Gene Therapies … margaret L smith on Novel Targeted Gene Therapies … Blogroll
-
-
-
-
-
-
-
-
